PortalPublikationenLiquid Biopsies

Liquid Biopsies

Standard

Liquid Biopsies. / Lianidou, Evi; Pantel, K.

in: GENE CHROMOSOME CANC, Jahrgang 58, Nr. 4, 04.2019, S. 219-232.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Lianidou, E & Pantel, K 2019, 'Liquid Biopsies', GENE CHROMOSOME CANC, Jg. 58, Nr. 4, S. 219-232. https://doi.org/10.1002/gcc.22695

APA

Lianidou, E., & Pantel, K. (2019). Liquid Biopsies. GENE CHROMOSOME CANC, 58(4), 219-232. https://doi.org/10.1002/gcc.22695

Vancouver

Lianidou E, Pantel K. Liquid Biopsies. GENE CHROMOSOME CANC. 2019 Apr;58(4):219-232. https://doi.org/10.1002/gcc.22695

Bibtex

@article{3edfbf06818b48a3917a901fcfdd4614,
title = "Liquid Biopsies",
abstract = "Liquid biopsy is based on minimally invasive blood tests and has a high potential to significantly change the therapeutic strategy in cancer patients, providing an extremely powerful and reliable noninvasive clinical tool for the individual molecular profiling of patients in real time. Liquid biopsy approaches include the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating miRNAs, and tumor-derived extracellular vesicles (EVs) that are shed from primary tumors and their metastatic sites into peripheral blood. The major advantage of liquid biopsy analysis is that it is minimally invasive, and can be serially repeated, thus allowing extracting information from the tumor in real time. Moreover, the identification of predictive biomarkers in peripheral blood that can monitor response to therapy in real time holds a very strong potential for novel approaches in the therapeutic management of cancer patients. In this review, we summarize recent knowledge on CTCs and ctDNA and discuss future trends in the field.",
keywords = "Journal Article, Review, Circulating Tumor DNA/genetics, Biomarkers, Tumor/blood, Epigenesis, Genetic, Humans, Neoplasms/blood, Neoplastic Cells, Circulating/metabolism",
author = "Evi Lianidou and K Pantel",
note = "{\textcopyright} 2018 Wiley Periodicals, Inc.",
year = "2019",
month = apr,
doi = "10.1002/gcc.22695",
language = "English",
volume = "58",
pages = "219--232",
journal = "GENE CHROMOSOME CANC",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "4",

}

RIS

TY - JOUR

T1 - Liquid Biopsies

AU - Lianidou, Evi

AU - Pantel, K

N1 - © 2018 Wiley Periodicals, Inc.

PY - 2019/4

Y1 - 2019/4

N2 - Liquid biopsy is based on minimally invasive blood tests and has a high potential to significantly change the therapeutic strategy in cancer patients, providing an extremely powerful and reliable noninvasive clinical tool for the individual molecular profiling of patients in real time. Liquid biopsy approaches include the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating miRNAs, and tumor-derived extracellular vesicles (EVs) that are shed from primary tumors and their metastatic sites into peripheral blood. The major advantage of liquid biopsy analysis is that it is minimally invasive, and can be serially repeated, thus allowing extracting information from the tumor in real time. Moreover, the identification of predictive biomarkers in peripheral blood that can monitor response to therapy in real time holds a very strong potential for novel approaches in the therapeutic management of cancer patients. In this review, we summarize recent knowledge on CTCs and ctDNA and discuss future trends in the field.

AB - Liquid biopsy is based on minimally invasive blood tests and has a high potential to significantly change the therapeutic strategy in cancer patients, providing an extremely powerful and reliable noninvasive clinical tool for the individual molecular profiling of patients in real time. Liquid biopsy approaches include the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating miRNAs, and tumor-derived extracellular vesicles (EVs) that are shed from primary tumors and their metastatic sites into peripheral blood. The major advantage of liquid biopsy analysis is that it is minimally invasive, and can be serially repeated, thus allowing extracting information from the tumor in real time. Moreover, the identification of predictive biomarkers in peripheral blood that can monitor response to therapy in real time holds a very strong potential for novel approaches in the therapeutic management of cancer patients. In this review, we summarize recent knowledge on CTCs and ctDNA and discuss future trends in the field.

KW - Journal Article

KW - Review

KW - Circulating Tumor DNA/genetics

KW - Biomarkers, Tumor/blood

KW - Epigenesis, Genetic

KW - Humans

KW - Neoplasms/blood

KW - Neoplastic Cells, Circulating/metabolism

U2 - 10.1002/gcc.22695

DO - 10.1002/gcc.22695

M3 - SCORING: Review article

C2 - 30382599

VL - 58

SP - 219

EP - 232

JO - GENE CHROMOSOME CANC

JF - GENE CHROMOSOME CANC

SN - 1045-2257

IS - 4

ER -